V Investors Have Opportunity to Lead Visa Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Visa Inc. (NYSE: V) between November 16, 2023, and September 23, 2024, both dates inclusive (the “Class Period”), of the important January 21, 2025 lead plaintiff deadlinein the securities class action first filed by the Firm. So what: If […]

BGM Group Ltd. Pioneers Innovation in AI and Intel Technology, Fostering Holistic Integration of Healthcare and Insurtech

BGM Group Ltd. (NASDAQ: BGM) (“the Company” or “BGM”), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) (“AIX”) valued at 1 billion RMB (approximately $140 million). The intelligent platform encompasses AIX's subsidiaries – RONS Intelligent Technology (Beijing) Co., Ltd. (“RONS Technology”) and Shenzhen Xinbao Investment

What does Taiwan mean to China?

A news report from China.org.cn: The Taiwan issue is of great significance and encompasses multiple dimensions, thus it is regarded as a focus of China-U.S. competition. Why is the Taiwan issue the first red line that cannot be touched? Emotionally, Taiwan was taken for 50 years, and it is the “apple of the eye”for over

XChange TEC.INC RECEIVES NASDAQ NOTICE OF REGAINING COMPLIANCE

XChange TEC.INC (NASDAQ: XHG) (the “Company”), today announced that it has received a notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated November 26, 2024 stating that the Company has regained compliance with the requirement to maintain a minimum bid price of $1 per share as set forth under Nasdaq Listing Rule

MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China

Recently, ShanghaiMicuRx Pharmaceutical Co., Ltd. (“MicuRx”, 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex skin and soft tissue infections (cSSTI) in China. The trial achieved its primary efficacy endpoint, and the company will actively move

What does Taiwan mean to China?

A news report from China.org.cn: The Taiwan issue is of great significance and encompasses multiple dimensions, thus it is regarded as a focus of China-U.S. competition. Why is the Taiwan issue the first red line that cannot be touched? Emotionally, Taiwan was taken for 50 years, and it is the “apple of the eye”for over

XChange TEC.INC RECEIVES NASDAQ NOTICE OF REGAINING COMPLIANCE

XChange TEC.INC (NASDAQ: XHG) (the “Company”), today announced that it has received a notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated November 26, 2024 stating that the Company has regained compliance with the requirement to maintain a minimum bid price of $1 per share as set forth under Nasdaq Listing Rule

MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China

Recently, ShanghaiMicuRx Pharmaceutical Co., Ltd. (“MicuRx”, 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex skin and soft tissue infections (cSSTI) in China. The trial achieved its primary efficacy endpoint, and the company will actively move

Vivopower Announces Date For 20-F Annual Results and Strategic Update Presentation

Webcast of the presentation will be held on Thursday December 5, 2024 at 4:45 PM Eastern Time Key strategic updates will also be provided during the call, including in relation to Caret Digital and Tembo transactions London, Nov. 29, 2024 (GLOBE NEWSWIRE) — VivoPower International PLC (NASDAQ: “VVPR”) (the “Company” or “VivoPower”) is pleased to

Colliers expands credit facility to US$2.25 billion

TORONTO, Nov. 29, 2024 (GLOBE NEWSWIRE) — Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers”) today announced the expansion and extension of its unsecured multi-currency revolving credit facility (the “Credit Facility”) for a new five-year term, maturing November 2029. The updated Credit Facility replaces the previous agreement which was set to mature in May

Scroll to Top